Clinical Trial Search

Primary: The Primary Safety Endpoint for This Study is the Composite Safety Endpoint (CSE) Defined as the Proportion of Patients With Early-onset and Late-onset Serious Adverse…

Primary: Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group — 2; 2; 9; 2…

Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants

Primary: Safety: Number of Participants With Prespecified Primary Safety Events Within 30 Days of Index Procedure. — 0 Participants

Primary: Safety at 30 Days — 1 Participants

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…

Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants

Primary: Number of Participants With Primary Adverse Events (PAEs) — 0; 0; 0 Participants

Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants

Primary: Percentage of Patients in Whom ACap™ Confirm Algorithm is Programmed Safely to ON During the First 12 Months. — 61.9 percentage of patients

Primary: Safety: Number of Participants With at Least One Primary Safety Event — 1; 1 Participants

Primary: Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion — 92 participants

Primary: Aortic Velocity Time Integral (VTI) — 22.4; 21.7; 19.4; 18.1 cm

Primary: Time to Imaging — 28.1; 7.1 hours

Primary: Number of Participants With Symptomatic Rhythm Detection up to 90 Days — 69; 11 Participants

Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants

Primary: Number of Participants With Successful Pulmonary Vein Isolation — 53 participants

Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95

Primary: Uterine Contractions — 3.18; 3.78; 3.20 minutes

Primary: Number of Patients With Pre-specified Safety Endpoints Occurring in the First 30 Days Post-index Procedure or Hospital Discharge, Whichever is Longer. — 3 Participants

Primary: Effectiveness: Percentage of Participants Free of Chronic Treatment Failure (CTF) Through 36 Months — 66.9 Percentage of participants — p=<0.001

Primary: Rate of Symptomatic Atrial Tachycardia/Atrial Fibrillation Episodes Per Subject Per Month — 2.0; 1.8 Episodes per subject per month — p=0.629

Primary: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention. — 123.2; 126.7 mean fluorescence intensity (MFI)

Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0.0; 0.0; 1.5; 1.5 percentage of participants

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants

Primary: Atrial Fibrillation Dominant Frequency

Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0; 0; 0; 0 Percentage of participants

Primary: Pivotal Main Phase Modified Intent-To-Treat (mITT) Analysis Set: Number of Participants With Primary Adverse Events (PAEs) — 8 Participants